U.S. Over-the-Counter Glucose Biosensors Market Size, Share & Trends Analysis Report By End-use (Healthcare Professional Offices (HCPs), Specialty Clinics, Homecare), By Key Companies, Competitive Analysis,- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2034

U.S. Over-the-Counter Glucose Biosensors Market Size and Growth

The U.S. over-the-counter glucose biosensors market size was exhibited at USD 117.51 million in 2024 and is projected to hit around USD 352.16 million by 2034, growing at a CAGR of 11.6% during the forecast period 2025 to 2034.

This growth is attributed to the increasing prevalence of diabetes and prediabetes, the shift towards preventive healthcare, and the increased adoption of glucose biosensors by athletes are some of the major factors driving market growth. Moreover, the aging population of the country further contributes to this growth as this age group is significantly vulnerable to chronic diseases such as diabetes, which increases the demand for effective solutions such as glucose biosensors.

The increase in the prevalence of diabetes due to aging, obesity, and unhealthy lifestyle is one of the factors contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Obesity is a major factor leading to diabetes. According to CBS News published in September 2024, approximately 30% of adults were classified as obese, with a body mass index (BMI) of 30 or higher in 2020. Furthermore, the CDC reported an increase in the adult obesity rate to 41.9% by 2020. Currently, based on survey data from 2021 to 2023, the CDC estimates that 40.3% of adults are obese. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimates that there were 537 million adults (aged 20-79) living with diabetes in 2021, and this number is expected to increase to 642 million by 2040. The IDF also reports that the prevalence of diabetes is growing globally, with the highest increase witnessed in low- and middle-income countries.

In the U.S., diabetes is a widespread health issue affecting millions of people. According to the CDC, as of 2024, 11.6% of the entire U.S. population-about 38.4 million people of all ages-has been diagnosed with diabetes. The percentage of adults aged 18 or older is even higher, with 14.7% or 38.1 million people affected. Around 8.7 million adults with diabetes were unaware of their condition or did not report it, representing 22.8% of all adults with diabetes and 3.4% of all U.S. adults. The risk of diabetes increases with age, with the percentage of adults with diabetes peaking at 29.2% among those aged 65 or above. These statistics highlight the significant impact that diabetes has on the U.S. population.

Moreover, the shift towards preventive healthcare is also contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Consumers increasingly prioritize health management to avoid chronic diseases such as diabetes, driven by rising awareness, government initiatives, and technological advancements. Preventive healthcare emphasizes early detection and continuous monitoring, fueling demand for accessible and user-friendly glucose monitoring devices.

OTC glucose biosensors such as Stelo and Lingo provide individuals with convenient, non-prescription options to monitor blood glucose levels at home. These devices offer ease of use with compact designs and seamless smartphone integration for real-time tracking and data analysis. Stelo and Lingo support proactive health management, enabling users to detect early changes in their glucose levels and take timely action, promoting a preventive approach to diabetes care.

Report Scope of U.S. Over-the-Counter Glucose Biosensors Market

U.S. Over-the-Counter Glucose Biosensors Market By End-use Insights

Homecare dominated the market and accounted for the largest revenue share of 50.0% in 2024 and is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of diabetes in the elderly population and the growing demand for convenient, patient-centric healthcare solutions. OTC glucose biosensors, which allow patients to monitor their blood glucose levels without requiring a prescription, are witnessing demand among individuals managing diabetes at home.

The adoption of these devices in the homecare segment is supported by the advancements in sensor technology, which have improved accuracy, ease of use, and affordability. Similarly, the accessibility of OTC glucose biosensors has reduced barriers for underserved populations, including those without significant access to healthcare facilities. Additionally, the increasing shift toward value-based care in the U.S. healthcare system emphasizes cost-effective management, which homecare solutions address effectively.

The Healthcare Professional Offices (HCPs) segment, which includes private practices and outpatient settings managed by primary care physicians, nurse practitioners (NPs), and physician assistants (PAs), is witnessing significant growth in the U.S. OTC glucose biosensors market. As more patients seek regular monitoring of their blood glucose levels, HCPs are adopting advanced glucose biosensors to enhance patient care. According to the State of the Primary Care Workforce, 2023, there were 268,297 primary care physicians in the U.S in 2021.

Moreover, according to the same source, there were 26,455 PAs and 270,660 NPs working in primary care in the country. This surge in the number of NPs and PAs indicates a significant shift towards a more collaborative and accessible model of healthcare delivery, particularly in managing chronic conditions such as diabetes. With more providers available to implement and utilize advanced glucose biosensors, HCPs are expected to meet the rising demand for effective diabetes management solutions, thereby contributing to the segment growth.

Some of the prominent players in the U.S. over-the-counter glucose biosensors market include:

• DexCom, Inc.
• Abbott

U.S. Over-the-Counter Glucose Biosensors Market Recent Developments

• In June 2024, Abbott received FDA clearance for its two new over-the-counter continuous glucose monitoring systems, Libre Rio and Lingo. Lingo targets consumers seeking to improve their health, while Libre Rio is designed for people aged 18 years and above with Type 2 diabetes who don't use insulin. Both systems leverage Abbott's advanced FreeStyle Libre technology to enhance glucose management and overall wellness.
  
  
• In March 2024, Dexcom received FDA clearance for Stelo, the first OTC glucose biosensor, for adults with Type 2 diabetes not using insulin. This innovation enhances access to continuous glucose monitoring technology in the country.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. over-the-counter glucose biosensors market

By End-use

• Healthcare Professional Offices (HCPs)
• Specialty Clinics
• Homecare